issued
on 19 Nov 2024
Last Applicant/ Owned by
238 Main Street, 9th Floor
Cambridge
MA
02142
Serial Number
98209503 filed on 04th Oct 2023
Registration Number
N/A
Correspondent Address
John V. Hobgood, Esquire
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
Pharmaceutical and biological preparations based on base editing, base modification, nucleobase editing, nucleobase modification, nucleic acid editing, gene editing, gene modification, gene modulation, gene reprogramming, gene therapy, genome editing, genome modification, cell therapy, cellular modification, tissue modification, and organ modification for use in human therapeutics for the treatmen Read More
Pharmaceutical and biological preparations based on base editing, base modification, nucleobase editing, nucleobase modification, nucleic acid editing, gene editing, gene modification, gene modulation, gene reprogramming, gene therapy, genome editing, genome modification, cell therapy, cellular modification, tissue modification, and organ modification for use in human therapeutics for the treatment of Sickle Cell Disease, Beta Thalassemia, Alpha-1 Antitrypsin Deficiency, Glycogen Storage Disease Ia, Cancer, T-Cell Cancer, T-Cell Acute Lymphoblastic Leukemia, CD7 positive Acute Myeloid Leukemia, and Stargardt Disease
N/A
N/A
No 98209503
No Service/Collective Mark
No 2216087.131
No
No
No
No
No
No
No
No
Status Date | Action Taken |
---|---|
19th Nov 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
08th Oct 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
08th Oct 2024 | PUBLISHED FOR OPPOSITION |
18th Sep 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
04th Sep 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
22nd Aug 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
22nd Aug 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
22nd Aug 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
30th May 2024 | EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED |
30th May 2024 | EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED |